Literature DB >> 10807522

Unusual patterns of alloimmunity evoked by allogeneic liver parenchymal cells.

G L Bumgardner1, C G Orosz.   

Abstract

Despite the widely accepted view of the liver as an immunoprivileged tissue, purified allogeneic liver parenchymal cells delivered to the liver of a recipient mouse are highly antigenic. A functional transgenic model of hepatocyte transplantation in mice is used to explore host immune responses to allogeneic hepatocytes. Transplanted hepatocytes expressing human alpha-1-antitrypsin (hA1AT) are monitored for survival by the secretion of the transgene product hA1AT. Transplantation of transgenic hepatocytes into syngeneic or immunoincompetent severe combined immunodeficiency disease (SCID) mice results in indefinite hepatocellular allograft survival. However, transplantation of transgenic hepatocytes into allogeneic hosts results in rapid hepatocyte rejection. This rejection response is associated with prominent delayed type hypersensitivity responses to cellular alloantigen but minimal donor-reactive humoral immunity. Hepatocyte rejection is not controlled by host treatment with anti-CD4 mAb despite the ability of the same treatment regimen to produce indefinite survival of donor-matched heart allografts. Host immune responses to allogeneic hepatocytes utilize CD40L/CD40 but not CD28/B7 co-stimulation, unlike the activation of both of these systems in responses to other allografts. Furthermore, C57BL/6 mice which have been induced by anti-CD4 mAb or gallium nitrate treatment to accept heart allografts promptly reject donor-matched transgenic hepatocytes. Studies in reconstituted SCID, CD4 knockout (KO), and CD8 KO mice demonstrate that hepatocyte rejection can be initiated independently by either CD4+ T cells or CD8+ T cells, which again diverges from what has been observed for most other types of allografts. This may account for the relative resistance to immunoprotection for hepatocellular allografts with conventional immunosuppressive agents and to immunoregulatory states induced by other allografts. Three models of hepatocyte rejection are discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10807522     DOI: 10.1034/j.1600-0528.2002.017409.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  22 in total

1.  Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling.

Authors:  Karl S Lang; Panco Georgiev; Mike Recher; Alexander A Navarini; Andreas Bergthaler; Mathias Heikenwalder; Nicola L Harris; Tobias Junt; Bernhard Odermatt; Pierre-Alain Clavien; Hanspeter Pircher; Shizuo Akira; Hans Hengartner; Rolf M Zinkernagel
Journal:  J Clin Invest       Date:  2006-09       Impact factor: 14.808

Review 2.  Anti-fibrogenic strategies and the regression of fibrosis.

Authors:  Tatiana Kisseleva; David A Brenner
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-04       Impact factor: 3.043

3.  Detection and characterization of hepatic engraftment of embryonic stem derived cells by fluorescent stereomicroscopy.

Authors:  Montserrat Caballero; Harry M Lightfoot; Michael Lapaglia; Andrew Pleasant; Seigo Hatada; Bruce A Cairns; Jeffrey H Fair
Journal:  J Surg Res       Date:  2007-05-31       Impact factor: 2.192

4.  Alloimmunization to transfused platelets requires priming of CD4+ T cells in the splenic microenvironment in a murine model.

Authors:  Christopher R Gilson; James C Zimring
Journal:  Transfusion       Date:  2011-10-07       Impact factor: 3.157

Review 5.  Immunological aspects of liver cell transplantation.

Authors:  Felix Oldhafer; Michael Bock; Christine S Falk; Florian W R Vondran
Journal:  World J Transplant       Date:  2016-03-24

6.  Hepatic stellate cells regulate immune response by way of induction of myeloid suppressor cells in mice.

Authors:  Hong-Shiue Chou; Ching-Chuan Hsieh; Horng-Ren Yang; Lianfu Wang; Yusuke Arakawa; Kathleen Brown; Qingyu Wu; Feng Lin; Marion Peters; John J Fung; Lina Lu; Shiguang Qian
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

Review 7.  Cell-based liver therapies: past, present and future.

Authors:  Valeria Iansante; Anil Chandrashekran; Anil Dhawan
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-07-05       Impact factor: 6.237

8.  Differential role of natural killer group 2D in recognition and cytotoxicity of hepatocyte-like cells derived from embryonic stem cells and induced pluripotent stem cells.

Authors:  Trinidad Cisneros; Danielle W Dillard; Xiumei Qu; Justin Arredondo-Guerrero; Martha Castro; Steven Schaffert; Renata Martin; Carlos O Esquivel; Sheri M Krams; Olivia M Martinez
Journal:  Am J Transplant       Date:  2019-01-16       Impact factor: 8.086

9.  mTOR Inhibition Suppresses Posttransplant Alloantibody Production Through Direct Inhibition of Alloprimed B Cells and Sparing of CD8+ Antibody-Suppressing T cells.

Authors:  Christina L Avila; Jason M Zimmerer; Steven M Elzein; Thomas A Pham; Mahmoud Abdel-Rasoul; Ginny L Bumgardner
Journal:  Transplantation       Date:  2016-09       Impact factor: 4.939

10.  Alloreactive (CD4-Independent) CD8+ T cells jeopardize long-term survival of intrahepatic islet allografts.

Authors:  K E Lunsford; K Jayanshankar; A M Eiring; P H Horne; M A Koester; D Gao; G L Bumgardner
Journal:  Am J Transplant       Date:  2008-06       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.